Pseudoephedrine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Pseudoephedrine: From Nasal Decongestant to Nasal Cavity Disease
One-Sentence Summary
Pseudoephedrine is a sympathomimetic decongestant long used to relieve nasal congestion associated with colds and allergic rhinitis. The TxGNN model’s top prediction — Nasal Cavity Disease — largely restates this already-known use rather than identifying a genuinely novel indication, with 19 clinical trials and 7 publications touching on related decongestant pharmacology, but only one trial testing pseudoephedrine directly against placebo.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current dataset (no Taiwan/US license record); pseudoephedrine is generally known as an oral α-adrenergic decongestant for nasal congestion |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L2 (1 completed Phase 2 RCT directly testing pseudoephedrine) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (DrugBank MOA field is a data gap). Based on general pharmacological knowledge, pseudoephedrine is an α-adrenergic receptor agonist that causes vasoconstriction of nasal mucosal blood vessels, reducing tissue edema and nasal airway resistance. This mechanism is the well-established basis for its use as an oral decongestant.
Because the predicted indication “Nasal Cavity Disease” sits mechanistically very close to pseudoephedrine’s known decongestant action, the prediction is biologically plausible — but it should be read as confirmatory of existing pharmacology rather than a novel repurposing signal. The evidence pack does not contain the drug’s actual approved indication (original_indications is empty and no license records exist), so the degree of true “repurposing novelty” cannot be confirmed from this dataset alone.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00804687 | Phase 2 | Completed | 53 | Randomized crossover comparing JNJ-39220675, pseudoephedrine, and placebo for allergic rhinitis symptom relief |
| NCT00562120 | Phase 2 | Completed | 21 | H3-receptor antagonist tested against nasal allergen-induced congestion using acoustic rhinometry |
| NCT03620513 | Phase 4 | Completed | 160 | Topical anesthesia vs. decongestant vs. combination to reduce discomfort during fiberoptic nasal endoscopy |
| NCT00517946 | N/A | Completed | 21 | MRI-based assessment of anti-allergy drug effects on nasal/sinus mucosal dimensions after allergen challenge |
| NCT03979209 | Phase 1 | Completed | 16 | Cortisol suppression risk with high-volume nasal mometasone irrigation at varying doses |
| NCT04048174 | N/A | Completed | 27 | Live probiotic bacteria (L. lactis) instilled into nasal/sinus cavities for refractory chronic rhinosinusitis |
| NCT00939393 | N/A | Completed | 72 | Endoscopic sinus surgery performed in-office vs. operating room, with/without balloon sinuplasty |
| NCT01886768 | N/A | Unknown | 212 | Double vs. single nasal pledget decongestion method for transnasal endoscopy tolerance |
| NCT05131958 | N/A | Unknown | 30 | Multiparametric (imaging, aerodynamic, acoustic, perceptual) evaluation of nasality in nasal polyposis |
| NCT06580210 | N/A | Recruiting | 114 | Mechanical decongestant seawater spray with essential oils for acute rhinitis with nasal obstruction |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11345158 | 2001 | Comparative pharmacology study | American Journal of Rhinology | Direct comparison of oral/topical decongestant effects of phenylpropanolamine vs. d-pseudoephedrine using acoustic rhinometry |
| 22794679 | 2012 | Review | Allergy and Asthma Proceedings | Overview chapter on nonallergic rhinitis, including decongestant mucosal mechanisms |
| 19769798 | 2009 | Preclinical (feline model) | American Journal of Rhinology & Allergy | Decongestant effects of D-pseudoephedrine, alone and with desloratadine, in feline nasal congestion model |
| 24492651 | 2014 | Preclinical pharmacology | J Pharmacology and Experimental Therapeutics | Selective α2c-adrenergic agonists evaluated in animal models of nasal congestion |
| 12387934 | 2002 | Preclinical (dog model) | J Pharmacological and Toxicological Methods | Chronic experimental dog model developed to study mechanism of nasal decongestant drugs |
| 11895194 | 2002 | Preclinical (dog model) | American Journal of Rhinology | Acoustic rhinometry-based dog model for studying nasal congestion pharmacology |
| 12962193 | 2003 | Preclinical (dog model) | American Journal of Rhinology | Allergic nasal congestion model in ragweed-sensitized dogs |
Safety Considerations
Please refer to the package insert for safety information.
(Note: Key warnings, contraindications, and drug-drug interaction data are not currently available for this compound in the evidence pack; TFDA label retrieval is flagged as a blocking data gap — see Conclusion.)
Other Predicted Indications (Lower Priority)
Two additional TxGNN predictions were scored for pseudoephedrine but do not currently warrant advancement:
- Acute laryngopharyngitis (score 99.73%, rank 7405) — Evidence Level L5, no supporting trials or literature; purely a model prediction. Recommendation: Hold.
- Allergic urticaria (score 99.14%, rank 18755) — Evidence Level L4; available trials and literature actually concern second-generation antihistamines (loratadine, fexofenadine, desloratadine), not pseudoephedrine itself. Mechanistic fit is weak, since pseudoephedrine is an α-adrenergic agonist rather than an H1-antihistamine, and urticaria is histamine-driven. Recommendation: Hold.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (nasal cavity disease) has only L2-level evidence (a single completed Phase 2 RCT directly testing pseudoephedrine) and largely reflects the drug’s already-known decongestant pharmacology rather than a novel repurposing opportunity. More importantly, TFDA/FDA label safety data (warnings, contraindications, DDI) are entirely missing — a Blocking-severity gap that prevents any S1 safety evaluation — and the drug currently has no market license record in the evaluated jurisdiction.
To proceed, the following is needed:
- Retrieve TFDA package insert (warnings/contraindications) — Blocking gap (DG001)
- Retrieve DrugBank mechanism of action detail — High-priority gap (DG002)
- Confirm the drug’s actual original/approved indication to properly assess repurposing novelty (original_indications field is currently empty)
- Clarify market/licensing status given “Not Marketed” flag before any regulatory strategy discussion
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.